info:eu-repo/semantics/article
Synthesis, crystal structure and cytotoxicity assays of a copper(II) nitrate complex with a tridentate ONO acylhydrazone ligand. Spectroscopic and theoretical studies of the complex and its ligand
Fecha
2019-03Registro en:
Burgos López, Yacelis del Socorro; del Pla, Julian; Balsa, Lucia Mariana; Leon, Ignacio Esteban; Echeverría, Gustavo Alberto; et al.; Synthesis, crystal structure and cytotoxicity assays of a copper(II) nitrate complex with a tridentate ONO acylhydrazone ligand. Spectroscopic and theoretical studies of the complex and its ligand; Elsevier Science Sa; Inorganica Chimica Acta; 487; 3-2019; 31-40
0020-1693
CONICET Digital
CONICET
Autor
Burgos López, Yacelis del Socorro
del Pla, Julian
Balsa, Lucia Mariana
Leon, Ignacio Esteban
Echeverría, Gustavo Alberto
Piro, Oscar Enrique
García Tojal, J.
Pis Diez, Reinaldo
Gonzalez Baro, Ana Cecilia
Parajón Costa, Beatriz Susana
Resumen
The new copper complex, [Cu(HL)(OH2)2](NO3), including the tridentate N-acyhydrazone derived from 4-hydroxy-benzohydrazide and 2-hydroxy-3-methoxybenzaldehyde, (H2L), has been synthesized and characterized in the solid state and in solution by spectroscopic (FTIR, Ra, UV?vis, EPR) methods. The results were compared with those obtained for the hydrazone ligand and complemented with computational methods based on DFT. The crystal structure of the complex has been determined by X-ray diffraction. It crystallizes in the triclinic P1¯ space group with Z = 2. The Cu(II) ion is in a distorted square pyramidal environment, coordinated to a planar HL- anion acting as a tridentate ligand. The 5-fold coordination is completed with two water molecules. It is arranged in the lattice as H-bonded ribbon-like polymers that extends along the [1 2 1] crystal direction. The cytotoxicity of the complex together with that of the H2L ligand and the copper ion were evaluated in vitro against five different human cancer cell lines namely A549 (lung), MG-63 (bone), MCF-7 and MDA-MB-231 (breast) and Jurkat (leukemia). The copper complex inhibits the cell viability in a dose dependent manner with a greater potency than the H2L ligand and the free copper ion displaying even higher antitumor activity than the well-known anticancer metallodrug cisplatin.